Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Host heterogeneity shapes clonal selection and organotropism in an extranodal lymphoma mouse model.

Cell death & disease·2026
Same author

Allogeneic mesenchymal stromal cells ameliorate lupus nephritis by regulating lipid metabolism via ASGR1.

Stem cell research & therapy·2026
Same author

FGFR1 frameshift mutation mediates the dysfunction of mesenchymal stem cells in craniofacial microsomia.

Stem cell research & therapy·2026
Same author

CCR2-overexpressing mesenchymal stromal cell-derived extracellular vesicles loaded with MPA ameliorate lupus nephritis.

Journal of nanobiotechnology·2026
Same author

Low-dose EGFR inhibition unlocks ferroptosis susceptibility to sensitize chemotherapy in EGFR-high triple-negative breast cancer.

The Journal of biological chemistry·2026
Same author

Identification of a novel c.150dup variant on the ABO*B.01 allele associated with a weak B phenotype.

Transfusion·2026

Related Experiment Video

Updated: Jul 18, 2025

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.7K

ZCCHC4 Promotes Osteosarcoma Progression by Upregulating ITGB1.

Lingli Luo1, Xiaojun Tang2, Linghua Liu3

  • 1Medical College, Hunan Polytechnic of Environment and Biology, Hengyang 421005, Hunan Province, China.

Critical Reviews in Eukaryotic Gene Expression
|August 22, 2023
PubMed
Summary

Zinc finger CCHC-type containing 4 (ZCCHC4) promotes osteosarcoma progression by upregulating integrin β1. Inhibiting ZCCHC4 may offer a new therapeutic strategy for osteosarcoma patients.

More Related Videos

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.2K
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

9.4K

Related Experiment Videos

Last Updated: Jul 18, 2025

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.7K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.2K
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

9.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Zinc finger CCHC-type containing 4 (ZCCHC4) is an RNA-binding protein involved in rRNA methylation and tumor cell proliferation.
  • The specific role of ZCCHC4 in osteosarcoma (OS) pathogenesis has not been previously elucidated.

Purpose of the Study:

  • To investigate the function and mechanism of ZCCHC4 in the progression of osteosarcoma.
  • To determine if ZCCHC4 could serve as a potential therapeutic target for OS.

Main Methods:

  • Quantitative real-time PCR and Western blotting were used to assess ZCCHC4 expression in OS tissues and cell lines.
  • Cell proliferation, epithelial-mesenchymal transition (EMT), and migration assays were performed following ZCCHC4 overexpression or knockdown.
  • Animal models were utilized to evaluate the in vivo effects of ZCCHC4 on tumor growth and metastasis.

Main Results:

  • ZCCHC4 exhibited significantly higher expression in osteosarcoma tissues and cell lines compared to normal controls.
  • ZCCHC4 overexpression enhanced OS cell proliferation, EMT, and motility, while ZCCHC4 silencing inhibited these processes.
  • ZCCHC4 was found to upregulate integrin β1 (ITGB1) expression, mediating its pro-tumorigenic effects.
  • In vivo studies demonstrated that ZCCHC4 knockdown suppressed osteosarcoma tumor growth and reduced metastasis.

Conclusions:

  • ZCCHC4 plays a critical role in promoting osteosarcoma progression, at least partly through the upregulation of ITGB1.
  • Targeting ZCCHC4 represents a promising novel therapeutic strategy for the treatment of osteosarcoma.